Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin degludec
Drug: insulin degludec/liraglutide
Drug: liraglutide

First Posted Date: 2011-04-15

Last Posted Date: 2018-02-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1663

Registration Number: NCT01336023

Locations: 🇬🇧
Novo Nordisk Investigational Site, Wrexham, United Kingdom

Safety of NNC 0123-0000-0338 in Healthy Subjects

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: NNC 0123-0000-0338
Drug: placebo
Drug: insulin glargine

First Posted Date: 2011-04-12

Last Posted Date: 2017-03-01

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 70

Registration Number: NCT01334034

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients

Phase 3

Completed

Conditions: Haemophilia B
Congenital Bleeding Disorder

Interventions: Drug: nonacog beta pegol

First Posted Date: 2011-04-11

Last Posted Date: 2017-07-28

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 74

Registration Number: NCT01333111

Locations: 🇬🇧
Novo Nordisk Investigational Site, Oxford, United Kingdom

Usability and Tolerability of the Norditropin NordiFlex® Injection Device in Children Never Previously Treated With Growth Hormone

Completed

Conditions: Growth Hormone Disorder
Growth Hormone Deficiency in Children
Genetic Disorder
Turner Syndrome
Foetal Growth Problem
Chronic Renal Insufficiency
Delivery Systems
Small for Gestational Age
Chronic Kidney Disease

Interventions: Drug: Norditropin NordiFlex®

First Posted Date: 2011-04-04

Last Posted Date: 2014-06-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 77

Registration Number: NCT01327924

Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin degludec

First Posted Date: 2011-03-30

Last Posted Date: 2017-03-06

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 222

Registration Number: NCT01326026

Locations: 🇪🇸
Novo Nordisk Investigational Site, Pozuelo de Alarcon, Spain

Effect of Oral Contraceptives After Administration of Semaglutide in Subjects With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: semaglutide
Drug: placebo
Drug: Microgyn®

First Posted Date: 2011-03-29

Last Posted Date: 2017-02-08

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 43

Registration Number: NCT01324505

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

Survey Evaluating the Psychosocial Effects of Living With Haemophilia

Completed

Conditions: Haemophilia B With Inhibitors
Congenital Bleeding Disorder
Haemophilia B
Haemophilia A With Inhibitors
Relatives to/Carers of Patients
Haemophilia A

Interventions: Other: No treatment given

First Posted Date: 2011-03-24

Last Posted Date: 2017-02-23

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1236

Registration Number: NCT01322620

Locations: 🇬🇧
Novo Nordisk Investigational Site, Crawley, United Kingdom

Safety and Tolerability of Insulin Degludec/Liraglutide (A3) in Healthy Subjects

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: insulin degludec/liraglutide
Drug: insulin degludec
Drug: liraglutide

First Posted Date: 2011-03-21

Last Posted Date: 2015-10-02

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 24

Registration Number: NCT01319240

Observational Study on Safety and Efficacy of NovoSeven® in Subjects With Congenital FVII Deficiency

Completed

Conditions: Congenital FVII Deficiency
Congenital Bleeding Disorder

Interventions: Drug: activated recombinant human factor VII

First Posted Date: 2011-03-11

Last Posted Date: 2014-10-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 36

Registration Number: NCT01312636

A Trial Investigating the Pharmacokinetic Properties of NN1218 in Subjects With Diabetes Mellitus, Type 1

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: Faster-acting insulin aspart
Drug: insulin aspart

First Posted Date: 2011-02-15

Last Posted Date: 2015-02-23

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 40

Registration Number: NCT01296438

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy